EPZ020411

Overview

EPZ020411 is a selective, blood-brain barrier-permeable PRMT6 inhibitor with an IC 50 of 0.010 μM. EPZ020411 blocks PRMT6 -mediated histone H3R2 methylation, reduces ROS production, and inhibits Apoptosis . EPZ020411 is applicable to research related to neuropathic pain, colorectal cancer , ototoxicity, hearing loss and glioblastoma.

Application

Products | Products > Disease Areas > Cancer | Products > Disease Areas > Neurological, Eye or Ear Disease | Products > Disease Areas > Digestive System Disease | Products > Disease Areas > CNS Neoplasm | Products > Disease Areas > Glioma | Products > Disease Areas > Colorectal Cancer | Products > Disease Areas > Digestive System Cancer | Products > Disease Areas > Pain | Products > Disease Areas > Ear Disease | Products > Disease Areas > Glioblastoma | Products > Signaling Pathways > Epigenetics | Products > Signaling Pathways > NF-κB | Products > Signaling Pathways > Metabolic Enzyme/Protease | Products > Signaling Pathways > Immunology/Inflammation | Products > Signaling Pathways > Apoptosis | Products > Research Areas > Neurological Disease | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Immunotherapy | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > Histone Methyltransferase | Products > Signaling Pathways > Reactive Oxygen Species (ROS) | Products > Signaling Pathways > Apoptosis

Product Information

• Catalog No.: HY-12970
• CAS No.: 1700663-41-7
• Molecular Formula: C25H38N4O3
• Molecular Weight: 442.59
• Purity: 98.07%
• Storage: 4°C, protect from light, stored under nitrogen * In solvent : -80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen)
• Solubility: ≥ 2.5 mg/mL (5.65 mM); Clear solution
• Availability: In-stock

Source

Original product source